• Scientists discover mechanism behind che

    From ScienceDaily@1:317/3 to All on Mon Apr 25 22:30:44 2022
    Scientists discover mechanism behind chemically induced suppression of
    fearful memories

    Date:
    April 25, 2022
    Source:
    Tokyo University of Science
    Summary:
    Fearful events negatively impact the brain. For instance,
    war veterans often go through post-traumatic stress disorder
    months after the cessation of the triggering event. Now, the
    precise mechanism of suppression of such fearful memories has
    been uncovered. Using a mouse model, the researchers identified
    the associated biochemical pathways, thus paving the way for the
    development and clinical evaluation of therapeutic compounds such
    as KNT-127.



    FULL STORY ========================================================================== Fearful events negatively impact the brain. For instance, war veterans
    often go through post-traumatic stress disorder months after the cessation
    of the triggering event. Now, in a study led by Tokyo University
    of Science researchers, the precise mechanism of suppression of such
    fearful memories has been uncovered. Using a mouse model, the researchers identified the associated biochemical pathways, thus paving the way for
    the development and clinical evaluation of therapeutic compounds such
    as KNT-127.


    ========================================================================== Tragic events like wars, famines, earthquakes, and accidents create
    fearful memories in our brain. These memories continue to haunt us
    even after the actual event has passed. Luckily, researchers from Tokyo University of Science (TUS) have recently been able to understand the
    hidden biochemical mechanisms involved in the selective suppression of
    fearful memories, which is called fear extinction. The researchers, who
    had previously demonstrated fear extinction in mice using the chemically synthesized compound "KNT-127," have now identified the underlying
    mechanism of this compound's action. Their findings have been published recently inFrontiers in Behavioral Neuroscience.

    Prof. Akiyoshi Saitoh, lead author of the study, and Professor at
    TUS, muses, "Drugs that treat fear-related diseases like anxiety and posttraumatic stress disorder must be able to help extinguish fear. We previously reported that KNT- 127, a selective agonist of the d-opioid
    receptor or DOP, facilitates contextual fear extinction in mice. However,
    its site of action in the brain and the underlying molecular mechanism
    remained elusive. We therefore investigated brain regions and cellular signaling pathways that we assumed would mediate the action of KNT-127
    on fear extinction." "We investigated the molecular mechanism of KNT-127-mediated suppression of fearful memories. We administered KNT-127
    to specific brain regions and identified the brain regions involved in promoting fear extinction via delta receptor activation," elaborates
    Dr. Daisuke Yamada, co-author of the study, and Assistant Professor
    at TUS.

    Using a mouse model, the research team performed fear conditioning
    test on laboratory mice. During fear conditioning, mice learn to
    associate a particular neutral conditioned stimulus with an aversive unconditioned stimulus (e.g., a mild electrical shock to the foot)
    and show a conditioned fear response (e.g., freezing).

    After the initial fear conditioning, the mice were re-exposed to the conditioning chamber for six minutes as part of the extinction training.

    Meanwhile, the fear-suppressing therapeutic "KNT-127" was microinjected
    into various regions of the brain, 30 minutes prior to re-exposure. The
    treated brain regions included the basolateral nucleus of the amygdala
    (BLA), the hippocampus (HPC), and the prelimbic (PL) or infralimbic
    subregions (IL) of the medial prefrontal cortex. The following day,
    the treated mice were re-exposed to the chamber for six minutes for
    memory testing. The fear-suppressing "KNT- 127" that infused into
    the BLA and IL, but not HPC or PL, significantly reduced the freezing
    response during re-exposure. Such an effect was not observed in mice
    that did not receive the KNT-127 treatment, thus confirming the fear- suppressing potential of this novel compound.

    Chemical compounds known to inhibit the actions of key intracellular
    signaling pathways like PI3K/Akt and MEK/ERK pathways reversed the
    therapeutic effect, thereby suggesting the key roles of these two pathways
    in influencing KNT-127- mediated fear extinction.

    The first author of the study, Ayako Kawaminami, who is currently pursuing research at TUS, says, "The selective DOP antagonist that we used for pretreatment antagonized the effect of KNT-127 administered into the
    BLA and IL. Further, local administration of MEK/ERK inhibitor into
    the BLA and of PI3K/Akt inhibitor into the IL abolished the effect of
    KNT-127. These findings strongly indicated that the effect of KNT-127
    is mediated by MEK/ERK signaling in the BLA, by PI3K/Akt signaling in
    the IL, and by DOPs in both brain regions.

    We have managed to show that DOPs play a role in fear extinction via
    distinct signaling pathways in the BLA and IL." PTSD and phobias are
    thought to be caused by the inappropriate or inadequate control of fear memories. Currently, serotonin reuptake inhibitors and benzodiazepines
    are prescribed during therapy. However, many patients do not derive
    significant therapeutic benefits from these drugs. Therefore, there is
    an urgent need for the development of new therapeutic agents that have
    a different mechanism of action from existing drugs.

    Dr. Hiroshi Nagase, a Professor at University of Tsukuba and a coauthor
    of the study, concludes, "We have succeeded in creating KNT-127 by
    successfully separating convulsion- and catalepsy-inducing actions,
    which has so far been extremely difficult. Our findings will provide
    useful and important information for the development of evidence-based therapeutics with a new mechanism of action, that is targeting DOP."
    Fighting fear with the right therapeutic is the need of the hour, as
    anxiety and stress increase globally, and the findings of this study
    could help us achieve this objective. We have our fingers crossed.


    ========================================================================== Story Source: Materials provided by Tokyo_University_of_Science. Note:
    Content may be edited for style and length.


    ========================================================================== Journal Reference:
    1. Ayako Kawaminami, Daisuke Yamada, Shoko Yanagisawa, Motoki
    Shirakata,
    Keita Iio, Hiroshi Nagase, Akiyoshi Saitoh. Selective d-Opioid
    Receptor Agonist, KNT-127, Facilitates Contextual Fear Extinction
    via Infralimbic Cortex and Amygdala in Mice. Frontiers in Behavioral
    Neuroscience, 2022; 16 DOI: 10.3389/fnbeh.2022.808232 ==========================================================================

    Link to news story: https://www.sciencedaily.com/releases/2022/04/220425104337.htm

    --- up 8 weeks, 10 hours, 51 minutes
    * Origin: -=> Castle Rock BBS <=- Now Husky HPT Powered! (1:317/3)